202 related articles for article (PubMed ID: 36126318)
1. Breakthrough COVID-19 in vaccinated patients with hematologic malignancies: results from the EPICOVIDEHA survey.
Pagano L; Salmanton-García J; Marchesi F; Blennow O; Gomes da Silva M; Glenthøj A; van Doesum J; Bilgin YM; López-García A; Itri F; Nunes Rodrigues R; Weinbergerová B; Farina F; Dragonetti G; Berg Venemyr C; van Praet J; Jaksic O; Valković T; Falces-Romero I; Martín-Pérez S; Jiménez M; Dávila-Valls J; Schönlein M; Ammatuna E; Meers S; Delia M; Stojanoski Z; Nordlander A; Lahmer T; Imre Pinczés L; Buquicchio C; Piukovics K; Ormazabal-Vélez I; Fracchiolla N; Samarkos M; Méndez GA; Hernández-Rivas JÁ; Espigado I; Cernan M; Petzer V; Lamure S; di Blasi R; Marques de Almedia J; Dargenio M; Biernat MM; Sciumè M; de Ramón C; de Jonge N; Batinić J; Aujayeb A; Marchetti M; Fouquet G; Fernández N; Zambrotta G; Sacchi MV; Guidetti A; Demirkan F; Prezioso L; Ráčil Z; Nucci M; Mladenović M; Liévin R; Hanáková M; Gräfe S; Sili U; Machado M; Cattaneo C; Adžić-Vukičević T; Verga L; Labrador J; Rahimli L; Bonanni M; Passamonti F; Pagliuca A; Corradini P; Hoenigl M; Koehler P; Busca A; Cornely OA
Blood; 2022 Dec; 140(26):2773-2787. PubMed ID: 36126318
[TBL] [Abstract][Full Text] [Related]
2. Passive pre-exposure immunization by tixagevimab/cilgavimab in patients with hematological malignancy and COVID-19: matched-paired analysis in the EPICOVIDEHA registry.
Marchesi F; Salmanton-García J; Buquicchio C; Itri F; Besson C; Dávila-Valls J; Martín-Pérez S; Fianchi L; Rahimli L; Tarantini G; Grifoni FI; Sciume M; Labrador J; Cordoba R; López-García A; Fracchiolla NS; Farina F; Ammatuna E; Cingolani A; García-Bordallo D; Gräfe SK; Bilgin YM; Dargenio M; González-López TJ; Guidetti A; Lahmer T; Lavilla-Rubira E; Méndez GA; Prezioso L; Schönlein M; Van Doesum J; Wolf D; Hersby DS; Magyari F; Van Praet J; Petzer V; Tascini C; Falces-Romero I; Glenthøj A; Cornely OA; Pagano L
J Hematol Oncol; 2023 Apr; 16(1):32. PubMed ID: 37005697
[TBL] [Abstract][Full Text] [Related]
3. Outcome of early treatment of SARS-CoV-2 infection in patients with haematological disorders.
Mikulska M; Testi D; Russo C; Balletto E; Sepulcri C; Bussini L; Dentone C; Magne F; Policarpo S; Campoli C; Miselli F; Cilli A; Ghiggi C; Aquino S; Di Grazia C; Giannella M; Giacobbe DR; Vena A; Raiola AM; Bonifazi F; Zinzani P; Cavo M; Lemoli R; Angelucci E; Viale P; Bassetti M; Bartoletti M
Br J Haematol; 2023 May; 201(4):628-639. PubMed ID: 36806152
[TBL] [Abstract][Full Text] [Related]
4. Outcome of COVID-19 patients with haematological malignancies after the introduction of vaccination and monoclonal antibodies: results from the HM-COV 2.0 study.
Oliva A; Cogliati Dezza F; Petrucci F; Romani FE; Morviducci M; Mirabelli FM; Cancelli F; Valeriani E; Marcelli G; Pugliese F; Turriziani O; Ricci P; Venditti M; Palange P; Mastroianni CM
Clin Exp Med; 2023 Oct; 23(6):2275-2285. PubMed ID: 36867292
[TBL] [Abstract][Full Text] [Related]
5. COVID-19 breakthrough infections, hospitalizations and mortality in fully vaccinated patients with hematologic malignancies: A clarion call for maintaining mitigation and ramping-up research.
Wang L; Kaelber DC; Xu R; Berger NA
Blood Rev; 2022 Jul; 54():100931. PubMed ID: 35120771
[TBL] [Abstract][Full Text] [Related]
6. Omicron related COVID-19 prevention and treatment measures for patients with hematological malignancy and strategies for modifying hematologic treatment regimes.
Guo W; Zheng Y; Feng S
Front Cell Infect Microbiol; 2023; 13():1207225. PubMed ID: 37928188
[TBL] [Abstract][Full Text] [Related]
7. Immunogenicity of the BNT162b2 COVID-19 mRNA vaccine and early clinical outcomes in patients with haematological malignancies in Lithuania: a national prospective cohort study.
Maneikis K; Šablauskas K; Ringelevičiūtė U; Vaitekėnaitė V; Čekauskienė R; Kryžauskaitė L; Naumovas D; Banys V; Pečeliūnas V; Beinortas T; Griškevičius L
Lancet Haematol; 2021 Aug; 8(8):e583-e592. PubMed ID: 34224668
[TBL] [Abstract][Full Text] [Related]
8. Early administration of SARS-CoV-2 monoclonal antibody reduces the risk of mortality in hematologic malignancy and hematopoietic cell transplant patients with COVID-19.
Jabr R; Khatri A; Anderson AD; Garcia LC; Viotti JB; Natori Y; Raja M; Camargo JF; Morris MI
Transpl Infect Dis; 2023 Feb; 25(1):e14006. PubMed ID: 36704987
[TBL] [Abstract][Full Text] [Related]
9. COVID-19 infection in adult patients with hematological malignancies: a European Hematology Association Survey (EPICOVIDEHA).
Pagano L; Salmanton-García J; Marchesi F; Busca A; Corradini P; Hoenigl M; Klimko N; Koehler P; Pagliuca A; Passamonti F; Verga L; Víšek B; Ilhan O; Nadali G; Weinbergerová B; Córdoba-Mascuñano R; Marchetti M; Collins GP; Farina F; Cattaneo C; Cabirta A; Gomes-Silva M; Itri F; van Doesum J; Ledoux MP; Čerňan M; Jakšić O; Duarte RF; Magliano G; Omrani AS; Fracchiolla NS; Kulasekararaj A; Valković T; Poulsen CB; Machado M; Glenthøj A; Stoma I; Ráčil Z; Piukovics K; Navrátil M; Emarah Z; Sili U; Maertens J; Blennow O; Bergantim R; García-Vidal C; Prezioso L; Guidetti A; Del Principe MI; Popova M; de Jonge N; Ormazabal-Vélez I; Fernández N; Falces-Romero I; Cuccaro A; Meers S; Buquicchio C; Antić D; Al-Khabori M; García-Sanz R; Biernat MM; Tisi MC; Sal E; Rahimli L; Čolović N; Schönlein M; Calbacho M; Tascini C; Miranda-Castillo C; Khanna N; Méndez GA; Petzer V; Novák J; Besson C; Duléry R; Lamure S; Nucci M; Zambrotta G; Žák P; Seval GC; Bonuomo V; Mayer J; López-García A; Sacchi MV; Booth S; Ciceri F; Oberti M; Salvini M; Izuzquiza M; Nunes-Rodrigues R; Ammatuna E; Obr A; Herbrecht R; Núñez-Martín-Buitrago L; Mancini V; Shwaylia H; Sciumè M; Essame J; Nygaard M; Batinić J; Gonzaga Y; Regalado-Artamendi I; Karlsson LK; Shapetska M; Hanakova M; El-Ashwah S; Borbényi Z; Çolak GM; Nordlander A; Dragonetti G; Maraglino AME; Rinaldi A; De Ramón-Sánchez C; Cornely OA;
J Hematol Oncol; 2021 Oct; 14(1):168. PubMed ID: 34649563
[TBL] [Abstract][Full Text] [Related]
10. Predictors of SARS-CoV-2 Omicron breakthrough infection after receipt of AZD7442 (tixagevimab-cilgavimab) for pre-exposure prophylaxis among hematologic malignancy patients.
Laracy JC; Yan J; Steiger SN; Tan CA; Cohen N; Robilotti EV; Fender J; Cohen S; Korde N; Lee-Teh M; Noy A; Oved JH; Roeker LE; Shah G; Babady NE; Kamboj M; Seo SK
Haematologica; 2023 Nov; 108(11):3058-3067. PubMed ID: 37345467
[TBL] [Abstract][Full Text] [Related]
11. Comprehensive Treatment of Hematological Patients with SARS-CoV-2 Infection Including Anti-SARS-CoV-2 Monoclonal Antibodies: A Single-Center Experience Case Series.
Boeckel GR; Hölscher SD; Bürger C; Jacob T; Krekeler C; Shumilov E; Reicherts C; Bleckmann A; Lenz G; Vollenberg R; Tepasse PR
Curr Oncol; 2022 Mar; 29(4):2312-2325. PubMed ID: 35448162
[TBL] [Abstract][Full Text] [Related]
12. COVID-19 infection in patients with haematological malignancies: A single-centre survey in the latest Omicron wave in China.
Zhu X; Jiang Q; Lu J; Sun Y; Zhao X; Yang S; Tang F; Yu W; Zhao T; Liu X; Jia J; Duan W; Hu L; Wang J; Liu Y; Peng N; Dou X; Ma R; Fu Q; Wang H; Liu K; Huang X; Jiang H
Br J Haematol; 2023 Jul; 202(1):31-39. PubMed ID: 37092433
[TBL] [Abstract][Full Text] [Related]
13. High-titer post-vaccine COVID-19 convalescent plasma for immunocompromised patients during the first omicron surge.
Tayyar R; Wong LK; Dahlen A; Shu E; Pandey S; Liu AY
Transpl Infect Dis; 2023 Apr; 25(2):e14055. PubMed ID: 36929619
[TBL] [Abstract][Full Text] [Related]
14. Outcomes of breakthrough COVID-19 infections in patients with hematologic malignancies.
Chien KS; Peterson CB; Young E; Chihara D; Manasanch EE; Ramdial JL; Thompson PA
Blood Adv; 2023 Oct; 7(19):5691-5697. PubMed ID: 36696472
[TBL] [Abstract][Full Text] [Related]
15. Are SARS-CoV-2 Antibodies Detectable in Human Milk After Vaccination Against COVID-19?
Scaggs Huang F
J Pediatric Infect Dis Soc; 2022 Apr; 11(4):126. PubMed ID: 35394545
[TBL] [Abstract][Full Text] [Related]
16. Vaccination for SARS-CoV-2 in Hematological Patients.
Riccardi N; Falcone M; Yahav D
Acta Haematol; 2022; 145(3):257-266. PubMed ID: 35220303
[TBL] [Abstract][Full Text] [Related]
17. SARS-CoV-2 primary and breakthrough infections in patients with cancer: Implications for patient care.
Wang L; Wang W; Xu R; Berger NA
Best Pract Res Clin Haematol; 2022 Sep; 35(3):101384. PubMed ID: 36494154
[TBL] [Abstract][Full Text] [Related]
18. COVID-19 in patients with hematologic malignancy.
Langerbeins P; Hallek M
Blood; 2022 Jul; 140(3):236-252. PubMed ID: 35544585
[TBL] [Abstract][Full Text] [Related]
19. Omicron BA.1-specific T-cell responses in adults vaccinated with CoronaVac or BNT162b2 in Hong Kong: an observational cohort study.
Mok CKP; Chen C; Zhao S; Sun Y; Yiu K; Chan TO; Lai HL; Lai KC; Lau KM; Ling KC; Chan KKP; Ng SS; Ko FW; Peiris M; Hui DS
Lancet Microbe; 2023 Jun; 4(6):e418-e430. PubMed ID: 37086735
[TBL] [Abstract][Full Text] [Related]
20. Study of efficacy and longevity of immune response to third and fourth doses of COVID-19 vaccines in patients with cancer: A single arm clinical trial.
Thakkar A; Pradhan K; Duva B; Carreno JM; Sahu S; Thiruthuvanathan V; Campbell S; Gallego S; Bhagat TD; Rivera J; Choudhary G; Olea R; Sabalza M; Shapiro LC; Lee M; Quinn R; Mantzaris I; Chu E; Will B; Pirofski LA; Krammer F; Verma A; Halmos B
Elife; 2023 Mar; 12():. PubMed ID: 36975207
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]